Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema

International Journal of Ophthalmology

Volumn 8, Issue 3, 2015, Pages 550-555

  Aksoy, Sibel ^a   Yilmaz, Gursel ^b   Akkoyun, Imren ^b   Yazici, Ayse Canan ^b  

^a stanbul Fatih Sultan Mehmet Training and Research Hospital   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Diabetic macular edema; Triamcinolone acetonide

Indexed keywords

EID: 84938854408     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2015.03.20     Document Type: Article

References (31)

1. Klein R, Klein B, Moss S, Cruickshanks KC. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7-16.
2. rd. The Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS Report Number 2. Ophthalmology 1987; 94(7): 761-774.
3. Fong DS, Ferris FL 3rd, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999; 127(2): 137-141.
4. Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology 1988; 95(12): 1673-1679.
5. Rutledge BK, Wallow IHL, Poulsen GL. Sub-pigment epithelial membrans after photocoagulation for diabetic macular edema. Arch Ophthalmol 1993; 111(5): 608-613.
6. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116(8): 1488-1497, 1497. e1.
7. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113(10): 1695. e1-15.
8. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. Öntravitreal Bevacizumab (Avastin) Therapy for Persistent Diffuse Diabetic Macular Edema. Retina 2006; 26(9): 999-1005.
9. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular edema treated by IVTA: a comparative, non-randomised study. Br J Ophthalmol 2005; 89(3): 321-326.
10. Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macular edema after unilateral injection of triamcinolone acetonide. Am J Ophthalmol 2004; 138(6): 970-977.
11. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14(4): 223-232.
12. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retin. Am J Pathol 2001; 158(1): 147-152.
13. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97(12): 2883-2890.
14. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C. Intravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology 2002; 109(5): 920-927.
15. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology2004; 111(11): 2044-2049.
16. Chakrabarti M, John SR, Chakrabarti A. Intravitreal monotherapy with bevacizumab (IVB) and triamcinolone acetonide (IVTA) versus combination therapy (IVB and IVTA) for recalcitrant diabetic macular edema. Kerela Journal of Ophthalmology 2009; 21(2): 139-148.
17. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 2011; 5: 1011-1016.
18. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92(1): 76-80.
19. Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M. Comparing IVTA and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmol 2012; 90(1): 56-60.
20. Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica 2012; 227(2): 100-106.
21. Song HJ, Lee JJ, Lee SJ. Comparison of the Short-Term Effects of IVTA and Bevacizumab Injection for Diabetic Macular Edema. Korean J Ophthalmol 2011; 25(3): 156-160.
22. Rensch F, Spandau UH, Wickenhauser A, Jonas JB. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol 2010; 88(2): e36-37.
23. Ophir A. Full-field 3-D optical coherence tomography imaging and treatment decision in diffuse diabetic macular edema. Invest Ophthalmol Vis Sci 2014; 55(5): 3052-3053.
24. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115(10): 1750-1755.
25. Kreutzer TC, Al Saeidi R, Kook D, Wolf A, Ulbig MW, Neubauer AS, Haritoglou C. Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema. Ophthalmologica 2010; 224(4): 258-264.
26. Zhang XL, Chen J, Zhang RJ, Wang WJ, Zhou Q, Qin XY. Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: a meta-analysis. Int J Ophthalmol 2013; 6(4): 546-552.
27. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114(5): 855-859.
28. Sawada O, Kawamura H, Kakinoki M, Ohji M. Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008 Oct; 246(10): 1379-1381.
29. Christoforidis JB, Carlton MM, Knopp MV, Hinkle GH. PET/CT imaging of I-124 radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 2011; 52(8): 5899-5903.
30. Kiddee W, Trope GE, Sheng L, Beltran-Agullo L, Smith M, Strungaru MH, Baath J, Buys YM. Intraocular pressure monitoring post-intravitreal steroids: a systematic review. Surv Ophthalmol 2013; 58(4): 291-310.
31. Shimura M, Nakazawa T, Yasuda K, Shiono T, Lida T, Sakamoto T, Nishida K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145(5): 854-861.